Parkinson’s disease motor symptoms improve with tavapadon

Patients with Parkinson’s disease experienced “significant and clinically meaningful” improvements in motor symptoms over 27 weeks with tavapadon, according to a study published in The Lancet Neurology. Tavapadon selectively targets D1/D5 receptors with reduced risk for adverse events that emerge with other dopaminergic treatment, Cindy Zadikoff, MD, executive medical director